Immune Checkpoint Inhibitor Therapy in the Clinical Management of Pretreated ES-SCLC

Download this slideset to review the latest data informing optimal use of immune checkpoint inhibition for the treatment of pretreated SCLC, including recommendations for immune-related adverse events.
Anna F. Farago, MD, PhD
Taofeek K. Owonikoko, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.39 MB
Released: July 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Related Content

Ross Camidge, MD, PhD, provides an expert perspective on ADCs in non-small-cell lung cancer as reported by Clinical Care Options (CCO)

D. Ross Camidge, MD, PhD Released: January 26, 2021

CCO Conference Coverage of WCLC 2020 with downloadable slides and experts’ commentaries of clinically relevant studies

Shirish M. Gadgeel, MD person default Nicolas Girard, MD, PhD Released: January 26, 2021

Downloadable CCO resource summarizing best practices for detection of RET gene alterations in lung and thyroid tumors

Released: January 21, 2021

Downloadable CCO resource summarizing efficacy data for recently FDA-approved next-generation RET inhibitors in lung and thyroid cancers

Released: January 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue